ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen

▴ ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen
Data presented may shift the treatment paradigm to 2-drug regimens (2DRs) for people living with HIV

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders will be presenting 25 abstracts during the HIV Glasgow 2020 congress, being held virtually 5-8 October.

The research will be presented from across its diverse portfolio of late-stage pipeline and licensed HIV treatments as well as findings from one of the largest, global, HIV patient-reported outcomes studies to date.

Key data presentations will include:
GEMINI 144-week and TANGO 96-week pivotal trial data that build upon the existing efficacy and safety profile of 2-drug regimen dolutegravir plus lamivudine in treatment naïve adults with HIV-1 and Dovato (dolutegravir/lamivudine) in virologically suppressed adults with HIV-1 STAT 24-week data which evaluated Dovato for rapid initiation of treatment after diagnosis in adults with HIV-1.

FLAIR 124-week findings for long-acting investigational cabotegravir and rilpivirine that further define its efficacy and safety profile, and analysis from the Phase 3 clinical development programme on factors influencing viral response to long-acting cabotegravir and rilpivirine, as well as an analysis of ATLAS-2M 48-week data of key outcomes in women, an often-under-represented population in clinical trials. Positive Perspectives Wave 2 data exploring gaps in achieving optimal self-rated health; challenges of a new HIV diagnosis in old age; self-care and involvement in HIV care.

Kimberly Smith, Head of Research & Development, ViiV Healthcare, said: “The advances we will be presenting from across the portfolio reflect our continued commitment to addressing the challenges of HIV and delivering therapies that really make a difference in people’s lives. Dovato has already delivered impressive safety and efficacy results for both treatment-naïve and treatment-experienced adults living with HIV. The new long-term results presented at Glasgow will go even further to characterise the durability of and resistance profile for this treatment. We’re excited to participate in the congress and share our latest findings with the community.”

Tags : #LatestPharmaNewsSep30 #LatestGskNewsSep30 #HIVGlasgow2020congress #LatestHIVTreatment #2drugregimenHIV

About the Author

Team Medicircle

Related Stories

Loading Please wait...

Trending Now

Daily Covid-19 cases in US will hit six digits soon, warns expertsOctober 24, 2020
ICMR backed Covaxin could be ready by June 2021 ; Bharat BiotechOctober 24, 2020
Sewage signals early warning of coronavirus outbreaksOctober 24, 2020
U.S. sets single-day record for COVID-19 cases during new surgeOctober 24, 2020
Expert finds limited effectiveness of convalescent plasma for covid-19 patientsOctober 24, 2020
87 year old homeopathic doctor provides home visits to COVID-19 patients in Chandrapur district of MaharashtraOctober 24, 2020
Steroids boost survival of preterm babies in low-resource settings, new study findsOctober 24, 2020
Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic CancerOctober 24, 2020
FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trialOctober 24, 2020
New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological CancersOctober 24, 2020
PMI Announces Medicago to Supply Up to 76 Million Doses of Its Plant-Derived COVID-19 Vaccine CandidateOctober 24, 2020
Gujarat records 1112 new cases of COVID-19 in last 24 hoursOctober 24, 2020
2377 COVID-19 patients recovered in Odisha in last 24 hoursOctober 24, 2020
Over 70 lakh people recovered from COVID-19 infection in country so farOctober 24, 2020
Health Minister Harsh Vardhan says next three months are crucial for country in fight against COVID-19October 24, 2020
Pfizer's Hospital Business section acquires Arixa Pharma October 24, 2020
India crosses the landmark of 10 crore total testsOctober 24, 2020
Bharat Biotech to conduct Phase 3 Trials Of Covaxin On 26,000 people across 25 sitesOctober 24, 2020
Catalent launches OptiGel DR, a delayed/enteric release Softgel October 24, 2020
Health Protection Campaign to be launched soon in ChhattisgarhOctober 24, 2020